© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 3-4, 173-182,
February 21, 1996
© 1996 Oxford University Press
The p53 Gene in Breast Cancer: Prognostic Value of Complementary DNA Sequencing Versus Immunohistochemistry
Department of Oncology, University of Uppsala Akademiska sjukhuset, Sweden
Department of Pathology, University of Uppsala Akademiska sjukhuset, Sweden
Departments of Surgery and Cancer Epidemiology, University of Uppsala Akademiska sjukhuset, Sweden
Pharmacia Biotech AB Uppsala
Correspondence to: Jonas Bergh, M.D., Ph.D., Department of Oncology, University of Uppsala, Akademiska sjukhuset, S-751 85 Uppsala, Sweden.
BACKGROUND: Mutations in the p53 tumor suppressor gene (also known as TP53) have been detected in a wide variety of human cancers. In breast cancer, the presence of p53 gene alterations has been associated with worse prognosis.
PURPOSE: We compared a complementary DNA (cDNA)-based sequencing method and an immunohistochemical (IHC) method for their abilities to detect p53 mutations in breast cancer specimens. In addition, we determined the prognostic value of information obtained when these two methods were used.
METHODS: Specimens from 316 primary breast tumors were evaluated for the presence of mutant p53 protein by use of the mouse monoclonal antibody Pab 1801 (that recognizes both wild-type and mutant forms of p53) and standard IHC methods. In addition, the entire coding region of p53 genes expressed in these tumors was screened for mutations by combining reverse transcription, the polymerase chain reaction, and DNA sequencing. Probabilities for overall survival (OS), breast cancer-corrected survival (BCCS; death from breast cancer is the considered event), and relapse-free survival (RFS) were estimated by use of the Kaplan—Meier method, and survival curves for different patient subgroups were compared by use of the logrank method. All reported P values are from two-sided tests.
RESULTS: Sixty-nine (22%) of 316 tumors had p53 gene mutations detected by the cDNA-based sequencing method; only 31 (45%) of these mutations were located in evolutionarily conserved portions of the p53 coding region. Sixty-four tumors (20% of the total) had elevated levels of p53 protein as detected by IHC, suggesting the presence of mutations. Of the sequencing-positive tumors (i.e., p53 mutant), 23 exhibited negative IHC reactions, indicating that IHC failed to detect 33% of the mutations. Furthermore, 19 of the IHC-positive tumors were sequencing negative (i.e., p53 wild-type), suggesting a 30% false-positive frequency with IHC. Four tumors (1.3% of the total) could not be analyzed by the cDNA-based sequencing method, and three tumors (1% of the total) could not be analyzed by IHC. The 5-year estimates for RFS, BCCS, and OS were significantly shorter for patients with p53 sequencing-positive tumors than for patients with sequencing-negative tumors (P = .001, P = .01, and P = .0003, respectively). Patients with IHC-positive tumors showed reduced survival in all three categories when compared with those with IHC-negative tumors, but the differences were not statistically significant.
CONCLUSIONS: Use of a cDNA-based sequencing method to determine the status of the p53 gene in primary breast cancers yielded better prognostic information than IHC performed with the Pab 1801 monoclonal antibody. [J Natl Cancer Inst 1996;88:173–82]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F.-C. Bidard, M.-C. Matthieu, P. Chollet, I. Raoefils, C. Abrial, J. Domont, M. Spielmann, S. Delaloge, F. Andre, and F. Penault-Llorca p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes Ann. Onc., July 1, 2008; 19(7): 1261 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Terzian, Y.-A. Suh, T. Iwakuma, S. M. Post, M. Neumann, G. A. Lang, C. S. Van Pelt, and G. Lozano The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss Genes & Dev., May 15, 2008; 22(10): 1337 - 1344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Choi, S. H. Roh, H. G. Kim, E. H. Han, H. G. Jeong, and K. W. Kang Enhanced expression of aromatase in p53-inactivated mammary epithelial cells Endocr. Relat. Cancer, March 1, 2008; 15(1): 139 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Poeta, J. Manola, M. A. Goldwasser, A. Forastiere, N. Benoit, J. A. Califano, J. A. Ridge, J. Goodwin, D. Kenady, J. Saunders, et al. TP53 Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck N. Engl. J. Med., December 20, 2007; 357(25): 2552 - 2561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Heaphy, K. B. Baumgartner, M. Bisoffi, R. N. Baumgartner, and J. K. Griffith Telomere DNA Content Predicts Breast Cancer Free Survival Interval Clin. Cancer Res., December 1, 2007; 13(23): 7037 - 7043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lonning, S Knappskog, V Staalesen, R Chrisanthar, and J. Lillehaug Breast cancer prognostication and prediction in the postgenomic era Ann. Onc., August 1, 2007; 18(8): 1293 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Di Leo, M Tanner, C Desmedt, M Paesmans, F Cardoso, V Durbecq, S Chan, T Perren, M Aapro, C Sotiriou, et al. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial Ann. Onc., June 1, 2007; 18(6): 997 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lu-Hesselmann, D. van Beuningen, V. Meineke, and E. Franke Influences of TP53 expression on cellular radiation response and its relevance to diagnostic biodosimetry for mission environmental monitoring Radiat Prot Dosimetry, December 1, 2006; 122(1-4): 237 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Silva, J. M. Garcia, C. Pena, V. Garcia, G. Dominguez, D. Suarez, F. I. Camacho, R. Espinosa, M. Provencio, P. Espana, et al. Implication of Polycomb Members Bmi-1, Mel-18, and Hpc-2 in the Regulation of p16INK4a, p14ARF, h-TERT, and c-Myc Expression in Primary Breast Carcinomas Clin. Cancer Res., December 1, 2006; 12(23): 6929 - 6936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Frasor, E. C. Chang, B. Komm, C.-Y. Lin, V. B. Vega, E. T. Liu, L. D. Miller, J. Smeds, J. Bergh, and B. S. Katzenellenbogen Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res., July 15, 2006; 66(14): 7334 - 7340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Lonning and A.-L. Borresen-Dale Interaction between p53 Staining and High-Dose Chemotherapy in Breast Cancer. Clin. Cancer Res., April 1, 2006; 12(7): 2289 - 2289. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Dominguez, J. M. Garcia, C. Pena, J. Silva, V. Garcia, L. Martinez, C. Maximiano, M. E. Gomez, J. A. Rivera, C. Garcia-Andrade, et al. {Delta}TAp73 Upregulation Correlates With Poor Prognosis in Human Tumors: Putative In Vivo Network Involving p73 Isoforms, p53, and E2F-1 J. Clin. Oncol., February 10, 2006; 24(5): 805 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P J Barrett-Lee Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S125 - S133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Andersson, L. Larsson, S. Klaar, L. Holmberg, J. Nilsson, M. Inganas, G. Carlsson, J. Ohd, C.-M. Rudenstam, B. Gustavsson, et al. Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF Ann. Onc., May 1, 2005; 16(5): 743 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Lindahl, G. Landberg, J. Ahlgren, H. Nordgren, T. Norberg, S. Klaar, L. Holmberg, and J. Bergh Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer Carcinogenesis, March 1, 2004; 25(3): 375 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Havrilesky, K. M. Darcy, H. Hamdan, R. L. Priore, J. Leon, J. Bell, and A. Berchuck Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., October 15, 2003; 21(20): 3814 - 3825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Marchetti, K. Cannita, E. Ricevuto, F. De Galitiis, Z. C. Di Rocco, A. Tessitore, R. Bisegna, G. Porzio, G. P. De Rubeis, T. Ventura, et al. Prognostic value of p53 molecular status in high-risk primary breast cancer Ann. Onc., May 1, 2003; 14(5): 704 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bonnefoi, S. Diebold-Berger, P. Therasse, A. Hamilton, M. van de Vijver, G. MacGrogan, L. Shepherd, N. Amaral, C. Duval, R. Drijkoningen, et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann. Onc., March 1, 2003; 14(3): 406 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Allegra, S. Paik, L. H. Colangelo, A. L. Parr, I. Kirsch, G. Kim, P. Klein, P. G. Johnston, N. Wolmark, and H. S. Wieand Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes' B and C Colon Cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study J. Clin. Oncol., January 15, 2003; 21(2): 241 - 250. [Abstract] [Full Text] [PDF]
|
|